Rennova Health, Inc. · OTC:RNVA
Rennova Health — Investor Presentation (June 2016)
22 slides from Rennova Health's investor presentation, June 2016
Slide 1: Diagnostics and Supportive Software Solutions to Healthcare Providers
Nasdaq: RNVA Diagnostics and Supportive Software Solutions to Healthcare Providers
Slide 2: Forward Looking Statements and Non-GAAP Information
Forward Looking Statements and Non-‐GAAP Information This presentation includes forward-‐looking statements about Rennova Health’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans,
Slide 3: Healthcare is Being Transformed: We are Rennova Health
Healthcare is Being Transformed We are Rennova Health 3
Slide 4: Key Investment Highlights
Key Investment Highlights • Five-‐year history of operations with multiple significant milestones • Substantial and profitable revenues from our core lab testing business • We operate in a very sizable and well established market place • Focused strategic growth plan from a solid foundation • We ha
Slide 5: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers • The diagnostics sector has changed dramatically in the last few years • Paper records and faxes meant different vendors to a medical provider could function side by side without communication • Electronic platforms and integration have
Slide 6: Rennova Offers a Single Source Solution for Medical Providers
Rennova Offers a Single Source Solution for Medical Providers Our core business is diagnostics: Historically >90% of our revenue has been derived from diagnostics That is changing: Clinical Lab Services 5 Clinical Laboratories Single Source Solution Revenue Software Cycle Solutions Management Propri
Slide 7: Recent Developments
Recent Developments Clinical Laboratory Operations Segment • 54% increase in monthly insured samples processed by our labs for the first two months of the second quarter of 2016 versus the average monthly insured samples for the first quarter of 2016. This increase in samples has resulted in: • 12%
Slide 8: Recent Developments
Recent Developments Supportive Software Solutions Segment • Our integrated software solution will result in a much more sustainable relationship with our customers • Added 29 new EHR clients in 2016 • 18 being added in the second quarter of 2016 • Launched Electronic Medication Administration Record
Slide 9: 2015 Accomplishments
2015 Accomplishments Completed Lab Development Supportive Software Development Merger & Nasdaq listing Launched in 4th Quarter of 2015: • Medical Mime EHR product & billing services designed for substance abuse treatment sector • CollabRx for cancer diagnostics and decision support • Rebranded to Re
Slide 10: Our Target Markets
Our Target Markets Drug and Alcohol R ehabilitation • Total Market S ize – estimated at $35 B illion* • Large and growing number of facilities in a fragmented m arket • Between 14,500 to 16,700 outpatient clinics* Market growth from high demand: • Over 23 m illion Americans are addicted to alcohol a
Slide 11: Rennova Health Licensing Map
Rennova Health Licensing Map 11
Slide 12: Our Payers
Our Payers • Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015 o Applied for Medicaid Licenses in 31 States o As of June 30, 2016, we possess Medicaid Licenses in 20 States • Current Third Party Insurance Payer Contracts o Blue Shield of California o Coventry (National Con
Slide 13: History in Numbers
History in Numbers $70,000,000 $59,429,000 $60,000,000 $50,000,000 $41,889,000 $40,000,000 $37,887,000 $30,000,000 $21,076,000 $19,749,000 $20,000,000 $14,775,000 $10,000,000 $3,993,000 $4,183,000 $3,714,000 $621,000 $-‐ 2011 2012 2013 2014 2015 Adjusted R evenues Adjusted EBITDA Reconciliation of
Slide 14: Select Income Statement Items
Select Income Statement Items Reconciliation of GAAP to Adjusted Measures (in thousands) 2011 2012 2013 2014 2015 GAAP Net Revenue $ 3,993 $ 21,076 $ 41,889 $ 57,928 $ 18,393 Reserve f or Aged Accounts Receivable -‐ -‐ -‐ 1,501 19,494 Adjusted Revenues $ 3,993 $ 21,076 $ 41,889 $ 59,429 $ 37,887
Slide 15: Strategy
Strategy 15
Slide 16: The Long Term Strategy
The Long Term Strategy Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders How? Build from a toxicology-‐focused company to: 1. A significant and diverse diagnostics business 2. Offering supportive software solutions that add value by
Slide 17: 2016 Goals
2016 Goals • Strengthen Core Diagnostic Business o Capitalize on recent disruption in toxicology sector o Increase Clinical testing o Grow Pharmacogenomics testing with Genomas o Launch DTC (direct to consumer) testing – StableSpot™ initial ambition, testosterone • Accelerate Growth and/or Launch: o
Slide 18: Online Training Program Launch to Deliver Increased Sales
Online Training Program Launch to Deliver Increased Sales Program Objectives: • Ensure consistency in messaging and information • Provide effective and easy to use platform • Make information accessible anytime and from anywhere • Enable opportunity for monitoring and assessment Initially for sales
Slide 19: Business Development Opportunities
Business Development Opportunities Epinex Diagnostics, Inc. Genomas Diabetes and rapid diagnostic Genomics based diagnostics -‐ tests for providers & consumers drug management solution 19
Slide 20: Rennova Management
Rennova Management Seamus Lagan • 20 years experience in the restructuring, development and CEO management of startup and small companies Jason Adams • CFO in behavorial health sector and S enior F inancial CFO Management of public companies Victoria Nemerson, Esq. • 25 years experience as a trial a
Slide 21: Board of Directors
Board of Directors Thomas Mika • 10 years as Chairman and CEO of a Nasdaq listed Company • Oversaw a number of public offerings. Chairman of Rennova, CEO of CollabRx (subsidiary) • Bachelor of Science degree in Microbiology, MBA Harvard Seamus Lagan • 20 years experience in the restructuring, develo
Slide 22: Key Investment Highlights
Key Investment Highlights • Five-‐year history of operations with multiple significant milestones • Substantial and profitable revenues from our core lab testing business • We operate in a very sizable and well established market place • Focused strategic growth plan based off a solid foundation •